

BrainsWay Deep TMS™ for Major Depressive Disorder




The only FDA-cleared TMS system that stimulates deeper and broader to more effectively alleviate symptoms of treatment-resistant depression.

Many Depression Patients are Unable to Achieve Remission with Medication or Psychotherapy Alone


- The widely cited STAR*D trial demonstrates diminishing clinical benefit and increasing incidence of side effects with successive pharmacological treatments.



Treatment Resistance



Treatment Intolerance



- While psychotherapy is a valuable treatment tool, it requires lengthy treatment and is best supplemented with medication or neuromodulation treatment for more challenging patients.

BrainsWay Deep TMS May Offer a Path to Remission for Treatment-Resistant Depression

Deep TMS has significant advantages that address limitations of existing traditional depression treatments

- Clinically proven to help many patients who don't respond to antidepressants or psychotherapy
- Has none of the systemic side effects associated with medication or short-term memory loss associated with ECT

Deep TMS Treatment Stimulates Areas of the Brain Associated with Depression Using the H1 Coil

- Treatment targets neuronal pathways related to control of motivation, reward, and pleasure—specifically the dorsolateral prefrontal cortex (DLPFC).




BrainsWay®

www.brainsway.com


Safety and Efficacy of BrainsWay Deep TMS in Alleviating Depression Symptoms has Repeatedly Been Demonstrated in Sham-Controlled Clinical Studies and Real Clinical Usage

- The only independent RCT comparing the H-Coil with medication, Figure-8 coil with medication,* and medication alone **demonstrated superior outcomes for BrainsWay.**



- In real clinical practice settings, **the majority of treatment-resistant depression patients have benefited from Deep TMS.**

Among patients who completed at least 30 sessions, **greater than 4 in 5 achieved response and approximately 2 in 3 achieved remission.**



*The Magstim® Rapid² device was used in this study.
(Magstim Company, Spring Gardens, UK)

Become a Leader in Your Community in the Treatment of Refractory Depression by Offering Deep TMS

BrainsWay's Practice Development Consultants work closely with you to build data-driven patient lead strategies and optimize practice workflow, helping ensure a strong return-on-investment.



Learn more about offering Deep TMS treatment for MDD in your practice

- ✓ **SPEAK** with a **BrainsWay representative**
- ✓ **SCAN** the **QR code** for more information
- ✓ **VISIT** the Knowledge Center at **www.brainsway.com**
- ✓ **CALL** us at **844-386-7001**
- ✓ **EMAIL** us at **DeepTMS@brainsway.com**



INDICATION: BrainsWay Deep TMS is indicated by the FDA for the treatment of depressive episodes and for decreasing Anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. FDA 510(k) No. K122288 (Model 102), FDA 510(k) No. K173540 (Model 104), FDA 510(k) No. K210201, No. K203735 (Models 102 & 104)

SAFETY INFORMATION: Patients should consult with their doctor before undergoing BrainsWay Deep TMS. The most common side effects include headaches and application site pain or discomfort. There is also a very rare risk of seizure associated with the treatment. Patients with metal in or around the head as in metal plates, implants, and stents should not undergo Deep TMS treatment.

REFERENCES:

Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905-17

Filipčić I et al. (2019) Efficacy of repetitive transcranial magnetic stimulation using a figure-8-coil or an H1-Coil in treatment of major depressive disorder; A randomized clinical trial. Journal of Psychiatric Research 114: 113-119

Tendler A, et al. Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis. Psychiatry Research. Vol 324, June 2023, 115179

Levkovitz Y, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015 Feb;14(1):64-73



BrainsWay®

www.brainsway.com

BrainsWay and Deep TMS are trademarks of BrainsWay Ltd. ©2023 BrainsWay. All Rights Reserved

BW-MDD-01 rev. 05/2023
MKT-0002-00 v1